Warp Sciences raises $215 million Series A to apply AI in drug building-block design

Former OpenAI head of science Kevin Weil announced the launch of Warp Sciences, a new startup aimed at accelerating the creation of molecular building blocks for drug discovery.

The company secured $215 million in a Series A financing round, attracting investors interested in the intersection of artificial intelligence and pharmaceutical chemistry.

Warp Sciences plans to use advanced AI models to design and synthesize chemical fragments that can serve as starting points for new medicines, targeting pharma companies seeking faster, more efficient R&D.

The founding team also includes technology veterans, bringing expertise from both AI research and drug development to bridge the gap between computational design and practical chemistry.